(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 6.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.33%.
Jazz Pharmaceuticals's revenue in 2025 is $4,086,695,000.On average, 21 Wall Street analysts forecast JAZZ's revenue for 2025 to be $261,014,855,127, with the lowest JAZZ revenue forecast at $247,305,964,293, and the highest JAZZ revenue forecast at $273,692,546,208. On average, 21 Wall Street analysts forecast JAZZ's revenue for 2026 to be $276,907,463,085, with the lowest JAZZ revenue forecast at $247,609,258,338, and the highest JAZZ revenue forecast at $313,120,772,058.
In 2027, JAZZ is forecast to generate $296,196,964,347 in revenue, with the lowest revenue forecast at $264,290,430,813 and the highest revenue forecast at $344,966,646,783.